Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 362

Sort by

Sort Order Select

Journal Articles

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Wanxing Zhang, Chaitanya Acharya, Steven Foltz, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, George Mulligan

Blood (2025) 146 (Supplement 1): 7470.

https://doi.org/10.1182/blood-2025-7470

Published: 2025

Journal Articles

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Michael Slade, Julie Fortier, Mark Fiala, Binod Dhakal, Hans Lee, Frank Kuhr, Wojciech Swat, Paola Tononi, Nicolo Manaresi, Alberto Ferrarini, Sarah Kelley, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 5851.

https://doi.org/10.1182/blood-2025-5851

Published: 2025

Journal Articles

Experiences of patients with multiple myeloma enrolled in high-deductible health plans: A mixed-methods study

Matthew Kaczynski, Akshay Mehta, Atman Shah, Enoch Park, Shelbie Fishman, Michael Slade, Ravi Vij, Mark Fiala

Blood (2025) 146 (Supplement 1): 4413.

https://doi.org/10.1182/blood-2025-4413

Published: 2025

Journal Articles

Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence

Blood (2025) 146 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2025-4955

Published: 2025

Journal Articles

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Blood (2025) 146 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2025-3949

Published: 2025

Journal Articles

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Blood (2025) 146 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2025-5723

Published: 2025

Journal Articles

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Blood (2025) 146 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2025-5801

Published: 2025

Journal Articles

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Steven Foltz, Reyka Jayasinghe, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, Chaitanya Acharya, Alexander Gout, George Mulligan

Blood (2025) 146 (Supplement 1): 4024.

https://doi.org/10.1182/blood-2025-4024

Published: 2025

Journal Articles

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Yamuna Kondapally, Julie Fortier, Antony Tin, Sarah Kelley, Derrick Renner, Mark Fiala, Angel Rodriguez, Minetta Liu, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Michael Slade

Blood (2025) 146 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2025-2219

Published: 2025

Journal Articles

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Michael Slade, Mark Fiala, Julie Fortier, Sarah Kelley, David Spencer, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 2218.

https://doi.org/10.1182/blood-2025-2218

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

Ravi Vij, Mark Fiala, David Cella, Brian Durie, David Kuter, Claudio Cerchione, Kamaraj Karunanithi, Jing Bo Li, Amanda Crosbie, Gabriela Hernandez-Rivera, Antoine Tinel, Thomas S. Marshall, Meghan Podolsky, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2025-6345

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Zachary Crees, Mark Schroeder, Michael Slade, Keith Stockerl-Goldstein, Ravi Vij, Ella Sorani, Irit Glicko-Kabir, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 5957.

https://doi.org/10.1182/blood-2025-5957

Published: 2025

Journal Articles

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Aarif Ahsan, Adam Luo, Cesar Rodriguez Valdes, Peter Voorhees, Anita D'Souza, Alfred Chung, Sascha Tuchman, Hana Safah, John Mckay, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Shaji Kumar, Thomas Doerr, Rajvineeth Kumar Pothacamury, Chetasi Talati, Brenda Chyla, Jeremy Ross

Blood (2025) 146 (Supplement 1): 5813.

https://doi.org/10.1182/blood-2025-5813

Published: 2025

Journal Articles

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

Julia Wang, Chenchen Peng, Reyka Jayasinghe, Michael Slade, Xiangwei Fang, Julie Fortier, Mark Fiala, Yuxuan Pan, Preet Lal, Yuting Zhao, Kiran Vij, Chaitanya Acharya, George Mulligan, John DiPersio, Feng Chen, Ravi Vij, Li Ding

Blood (2025) 146 (Supplement 1): 5804.

https://doi.org/10.1182/blood-2025-5804

Published: 2025

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, Ravi Vij, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark Fiala

Blood (2024) 144 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2024-203469

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Experiences of patients with multiple myeloma enrolled in high-deductible health plans: A mixed-methods study

Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only